---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Thymectomy"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Thymectomy. Topics: Thymectomy in nonthymomatous AChR antibody-positive disease: 2020 consensus update, MGTX randomized trial: 3-year results, MGTX extension: 5-year results, AAN practice advisory on thymectomy, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/thymectomy"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Thymectomy

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Thymectomy

<a id="topic-2.2.2.1.4-1"></a>

### Thymectomy in nonthymomatous AChR antibody-positive disease: 2020 consensus update

> “In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations (median 9, range 2–9).”
> “Thymectomy should be strongly considered in patients with AChR-Ab+ generalized MG if they fail to respond to an initial adequate trial of immunotherapy or have intolerable side effects from that therapy”
> “Current evidence does not support an indication for thymectomy in patients with MuSK, low-density lipoprotein receptor–related protein 4, or agrin antibodies”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.4-2"></a>

### MGTX randomized trial: 3-year results

> “A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001).”
> “Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis.”

Source: [Wolfe et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5189669/)

<a id="topic-2.2.2.1.4-3"></a>

### MGTX extension: 5-year results

> “Of 111 subjects who completed the 3-year MGTX trial, 68 (61%) entered the extension study between September 1, 2009 and August 26, 2015 (33 prednisone alone; 35 prednisone plus thymectomy).”
> “At 5 years, patients randomised to thymectomy plus prednisone continued to demonstrate improved clinical status compared to patients in the prednisone alone group based on time-weighted average QMG (5.47±3.87 vs. 9.34±5.08; 95% CI for the difference 0.71–7.04; p=0.0007) and lower average alternate-day prednisone requirements (24 mg±21 mg vs. 48±29 mg; 95% CI for the difference 12–36 mg; p=0.0002). The proportion of patients requiring hospitalisation for MG exacerbation (6% vs. 30%; 95% CI for the difference 7.1–42.1%; p=0.0105) was lower in the thymectomy group.”

Source: [Wolfe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6774753/)

<a id="topic-2.2.2.1.4-4"></a>

### AAN practice advisory on thymectomy

> “For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence).”
> “Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B).”

Source: [Gronseth et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32213645/)

<a id="topic-2.2.2.1.4-5"></a>

### Timing of thymectomy by age: Nordic guidance

> “In patients with non‐thymoma, generalized MG, AChR antibodies, and age below 50 years, thymectomy should be performed within 4 months from diagnosis.”
> “In patients with non‐thymoma generalized MG, AChR antibodies, and age 50–65 years, early thymectomy should be considered if minimal manifestations are not reached, or the patient has substantial side effects from treatment.”
> “Minimally invasive techniques are preferred with fewer perioperative complications, shorter hospitalization time, and minimal scars.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
